Fortibone

PreclinicalSmall molecule

FFrontier Medical and Dental College, Abbotabad

Fortibone is one of 19 small molecule programs targeting Osteopenia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteopeniaActive, not recruiting

OsteopeniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Osteopenia

#DrugCompanyPhaseTrials

Epidiolex

Estrace

Evista

Deltavit

HHyundai Pharmaceutical Co., LTD.

Approved

2 5

Jadelle

IItalian Network for Tumor Biotherapy Foundation

Forteo

Zometa

2 8

Prolia

Amgen

Phase 3

—9

Boniva

CConrado Roberto Hoffmann Filho

Phase 3

2 10

Ozempic

Novo Nordisk

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteopenia1 trial

Effectiveness of Calcium and Vitamin D, With and Without Collagen Peptide, in Enhancing Bone Mineral Density on Postmenopausal Women With Osteopenia

Completed·FFrontier Medical and Dental College, Abbotabad·N/A·NCT06464718·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fortibone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fortibone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fortibone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Frontier Medical and Dental College, Abbotabad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFrontier Medical and Dental College, Abbotabad

Fortibone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteopenia1 trial

References

Drug Info

Quick Facts

Related News